Arthritis anti-inflammatory treatment could halt immune system 'storm' to coronavirus

Doctors say anti-inflammatory treatment tocilizumab could save lives by halting the immune system 'storm' that has killed thousands of virus patients.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

With the onset of the global pandemic in 2020 of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), there has been increasing research activity around certain disease-modifying drugs that are used for the management of inflammatory disorders such as rheumatoid arthritis, spondyloarthrosis, psoriatic arthritis, systemic lupus erythematosus, and inflammatory bowel disease for managing coronavirus symptoms. In the conditions mentioned, many people are on long-term treatment with agents including hydroxychloroquine, tumor necrosis factor alpha (TNFα) inhibitor drugs, other biologic agents such as monoclonal an...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsOur study did not support the prophylactic use of antimalarials for COVID ‐19.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: BRIEF REPORT Source Type: research
Abstract Antimalaria drugs such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been administered to several inflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus, and infectious diseases such as acquired immune deficiency syndrome and influenza. Recently, several patients infected with novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were given HCQ, and showed a discrepant response. HCQ inhibits SARS-CoV-2 cell entry, and inflammatory cascade by interfering with lysosomal and endosomal activities, and autophagy, impeding virus-membrane fusion, and inhib...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
ConclusionIn this systematic review and meta ‐analysis, hydroxychloroquine use was not associated with benefit or harm with regard to COVID‐19 mortality. The evidence supporting the effect of other antirheumatic disease therapies in COVID‐19 is currently inconclusive.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
Authors: Hase R, Kurata R, Ishida K, Kurita T, Muranaka E, Mito H Abstract A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
CONCLUSIONS: Although the report mainly includes the most severe cases, its temporal and spatial trend supports the validity of the national surveillance system. More complete data are being acquired in order to both test the hypothesis that RMD patients may have a different outcome from that of the general population and determine the safety of immunomodulatory treatments. PMID: 32723435 [PubMed - in process]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Authors: Manfredi A, Luppi F, Cassone G, Vacchi C, Salvarani C, Sebastiani M Abstract INTRODUCTION: Main clinical manifestations of SARS-CoV-2 infection are characterized by fever, cough, dyspnoea and interstitial pneumonia frequently evolving in an acute respiratory distress syndrome (ARDS). AREAS COVERED: Features of coronavirus disease 2019 (COVID-19) pneumonia presents some common points with interstitial lung disease (ILD) both idiopathic and related to rheumatoid arthritis (RA), typically characterized by a chronic progression over some years and possibly complicated by acute exacerbation. The study of so...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
AbstractThromboses are severe complications of the coronavirus disease 2019 (COVID ‐19) caused by the novel severe acute respiratory system coronavirus 2 (SARS‐CoV‐2). The mechanism of COVID‐19‐associated thrombophilia is unknown; increasing global reports of antiphospholipid antibody (aPL)‐positivity in COVID‐19 suggest that the virus may induce antiphospholipid syn drome (APS), a separate autoimmune thrombotic illness1. Because laboratory criteria used to diagnose APS are neither strongly specific nor sensitive, and because clinical circumstances including anticoagulation alter the laboratory results, inter...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: LETTER TO THE EDITOR Source Type: research
ConclusionThese guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a “living document,” and future updates are anticipated.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
CONCLUSIONS: The incidence of these AEs does not appear above the background expected. These data are consistent with routine clinical observations and suggest the importance of pharmacovigilance. PMID: 32693646 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
More News: Actemra | Arthritis | Coronavirus | COVID-19 | Health | Rheumatology